Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience

Pancreatic adenocarcinoma is the fourth leading cause of cancer death. Recently, MM-398 (nanoliposomal irinotecan) was shown to be associated with significant improvement in outcome measures with acceptable toxicities when combined with 5-fluorouracil (5-FU)/leucovorin (LV) compared to 5-FU/LV alone...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Med Oncol
Huvudupphovsmän: Bupathi, M., Ahn, D. H., Wu, C., Ciombor, K. K., Stephens, J. A., Reardon, J., Goldstein, D. A., Bekaii-Saab, T.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2016
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4976592/
https://ncbi.nlm.nih.gov/pubmed/26995224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-016-0753-9
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk